S. D. Rubin

882 total citations
14 papers, 709 citations indexed

About

S. D. Rubin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, S. D. Rubin has authored 14 papers receiving a total of 709 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in S. D. Rubin's work include HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (5 papers) and Advanced Breast Cancer Therapies (3 papers). S. D. Rubin is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (5 papers) and Advanced Breast Cancer Therapies (3 papers). S. D. Rubin collaborates with scholars based in United States, United Kingdom and India. S. D. Rubin's co-authors include Harold J. Burstein, Kimberly Blackwell, S. Stein, Sandra Franco, Vanessa Salazar, Anna Maria Storniolo, Dario Palmieri, Patricia S. Steeg, Maria J. Merino and Eleazar Vega-Valle and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

S. D. Rubin

14 papers receiving 690 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. D. Rubin United States 8 559 264 191 180 123 14 709
R. Islam United States 7 531 0.9× 277 1.0× 207 1.1× 97 0.5× 59 0.5× 8 725
M. Beeram United States 16 452 0.8× 304 1.2× 406 2.1× 165 0.9× 77 0.6× 48 860
Hua-Zhong Zhang United States 12 224 0.4× 131 0.5× 226 1.2× 82 0.5× 57 0.5× 14 504
Chiara Lambertini Switzerland 15 607 1.1× 174 0.7× 250 1.3× 202 1.1× 57 0.5× 26 862
Nishan Tchekmedyian United States 10 522 0.9× 400 1.5× 297 1.6× 73 0.4× 51 0.4× 17 795
Amy Freyman United States 7 418 0.7× 326 1.2× 263 1.4× 97 0.5× 52 0.4× 12 657
Kim Pedersen Spain 12 761 1.4× 112 0.4× 351 1.8× 449 2.5× 96 0.8× 14 992
Ross Carruthers United Kingdom 12 414 0.7× 170 0.6× 352 1.8× 82 0.5× 217 1.8× 21 766
P.N. Munster United States 12 336 0.6× 119 0.5× 307 1.6× 49 0.3× 43 0.3× 18 584
Oliver Stoß Germany 10 532 1.0× 334 1.3× 471 2.5× 254 1.4× 43 0.3× 16 1.0k

Countries citing papers authored by S. D. Rubin

Since Specialization
Citations

This map shows the geographic impact of S. D. Rubin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. D. Rubin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. D. Rubin more than expected).

Fields of papers citing papers by S. D. Rubin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. D. Rubin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. D. Rubin. The network helps show where S. D. Rubin may publish in the future.

Co-authorship network of co-authors of S. D. Rubin

This figure shows the co-authorship network connecting the top 25 collaborators of S. D. Rubin. A scholar is included among the top collaborators of S. D. Rubin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. D. Rubin. S. D. Rubin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Sternberg, C., Robert E. Hawkins, Cezary Szczylik, et al.. (2011). A randomized, double-blind phase III study (VEG105192) of pazopanib (paz) versus placebo (pbo) in patients with advanced/metastatic renal cell carcinoma (mRCC): Updated safety results.. Journal of Clinical Oncology. 29(7_suppl). 313–313. 11 indexed citations
3.
Blackwell, Kimberly, Mark D. Pegram, Elizabeth Tan-Chiu, et al.. (2009). Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Annals of Oncology. 20(6). 1026–1031. 136 indexed citations
4.
5.
Gril, Brunilde, Dario Palmieri, Julie L. Bronder, et al.. (2008). Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain. JNCI Journal of the National Cancer Institute. 100(15). 1092–1103. 218 indexed citations
6.
Burstein, Harold J., Anna Maria Storniolo, Sandra Franco, et al.. (2008). A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Annals of Oncology. 19(6). 1068–1074. 171 indexed citations
7.
Lin, NU, Véronique Dièras, Hans‐Joachim Stemmler, et al.. (2008). A physician-reported neurological signs and symptoms worksheet (NSS WS) in EGF105084: A phase II study of lapatinib (lap) for pts with recurrent brain metastases (BM) from HER2+ breast cancer (BC). Journal of Clinical Oncology. 26(15_suppl). 1078–1078. 3 indexed citations
8.
9.
10.
Molina, Julian R., Charles Erlichman, Scott H. Kaufmann, et al.. (2007). A phase I study of lapatinib and topotecan in patients with solid tumors. Journal of Clinical Oncology. 25(18_suppl). 3598–3598. 2 indexed citations
11.
Geyer, Charles E., Anne Marie Martin, B. Newstat, et al.. (2007). Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data. Journal of Clinical Oncology. 25(18_suppl). 1035–1035. 26 indexed citations
12.
Hoff, Daniel D. Von, et al.. (2004). A Phase I and pharmacokinetic study of HMN-214, a novel oral polo-like kinase inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3034–3034. 10 indexed citations
13.
Hoff, Daniel D. Von, et al.. (2004). A Phase I and pharmacokinetic study of HMN-214, a novel oral polo-like kinase inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3034–3034. 6 indexed citations
14.
Bustelo, Xosé R., S. D. Rubin, Ki‐Ling Suen, Daniel R. Carrasco, & Mariano Barbacid. (1993). Developmental expression of the vav protooncogene.. PubMed. 4(4). 297–308. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Islam Breakdown of academic impact, for papers by M. Beeram Breakdown of academic impact, for papers by Hua-Zhong Zhang Breakdown of academic impact, for papers by Chiara Lambertini Breakdown of academic impact, for papers by Nishan Tchekmedyian Breakdown of academic impact, for papers by Amy Freyman Breakdown of academic impact, for papers by Kim Pedersen Breakdown of academic impact, for papers by Ross Carruthers Breakdown of academic impact, for papers by P.N. Munster Breakdown of academic impact, for papers by Oliver Stoß
Rankless by CCL
2026